CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...